Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pembrolizumab/quavonlimab - Merck Sharp & Dohme

Next Previous
X
Search
Drug Profile

Pembrolizumab/quavonlimab - Merck Sharp & Dohme

Alternative Names: Coformulation Pembrolizumab/quavonlimab - Merck Sharp & Dohme; MK 1308A; Pembrolizumab+quavonlimab; Quavonlimab+pembrolizumab; Quavonlimab/pembrolizumab - Merck Sharp & Dohme

Latest Information Update: 06 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Eisai Inc; Merck Sharp & Dohme
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal cell carcinoma
  • Phase II Colorectal cancer; Liver cancer; Malignant melanoma; Small cell lung cancer; Solid tumours

Most Recent Events

  • 13 Sep 2024 Efficacy and adverse events data from Phase-I/II clinical trials in Malignant melanoma presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 08 Apr 2024 Merck Sharp & Dohme completes the Phase-I/II clinical trials in Solid tumours (Combination therapy, Metastatic disease, Late-stage disease) in USA, Australia, Canada, Chile, France, Greece, Israel, Italy, Japan, New Zealand, Poland, South Korea, Spain, Sweden, South Africa (IV) (NCT03179436)
  • 05 Apr 2024 Efficacy and adverse events data from the phase Ib/II KEYNOTE-B98 trial in Small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top